TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06675526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detour
Description: Detour is a mobile game designed to assist youth with smoking cessation. First, Detour targets stimuli devaluation using a gamified go/no-go training. Second, the researchers aimed to reduce delay discounting in two ways; 1) players can replace neutral images in the go/no-go training with positive images from their own lives related to their future self; 2) players can set and monitor personal goals via the game, to promote future-self priming. Third, participants join a social shell comprising Instagram and TikTok content to provide psychoeducation about quitting smoking and to interact with fellow players who quit simultaneously. Finally, the timing and content of in-game messaging is personalized to each participant based on information provided in an ecological momentary assessment component and a stop plan filled out during the week before the quit attempt.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help brochure
Description: The brochure provides guidelines to independently design a stop-plan including questions about seeking support from others, strategies to fight cravings, and setting rewards for milestones after quitting. Participants will be encouraged to complete this stop-plan in week 0 of the intervention, so the week before quit day. Additionally, the brochure includes psychoeducational information that is valuable when planning to quit smoking.
Study: NCT06684886

Intervention type: OTHER
Intervention: Ankle Brachial Index
Description: Normal ABI ranges from 1.0 - 1.4~* Pressure is normally higher in the ankle than the arm.~* Values above 1.4 suggest a noncompressible calcified vessel.~* In diabetic or elderly patients, the limb vessels may be fibrotic or calcified. In this case, the vessel may be resistant to collapse by the blood pressure cuff, and a signal may be heard at high cuff pressures. The persistence of a signal at a high pressure in these individuals results in an artifactually elevated blood pressure value.~* An value below 0.9 is considered diagnostic of PAD.~* Values less than 0.5 suggests severe PAD.~* Individuals with such severe disease may not have sufficient blood flow to heal a fracture or surgical wound; they should be considered for revascularization if they have a non-healing ulcer.

Intervention type: OTHER
Intervention: Ankle Brachial Index
Description: Normal ABI ranges from 1.0 - 1.4~* Pressure is normally higher in the ankle than the arm.~* Values above 1.4 suggest a noncompressible calcified vessel.~* In diabetic or elderly patients, the limb vessels may be fibrotic or calcified. In this case, the vessel may be resistant to collapse by the blood pressure cuff, and a signal may be heard at high cuff pressures. The persistence of a signal at a high pressure in these individuals results in an artifactually elevated blood pressure value.~* An value below 0.9 is considered diagnostic of PAD.~* Values less than 0.5 suggests severe PAD.~* Individuals with such severe disease may not have sufficient blood flow to heal a fracture or surgical wound; they should be considered for revascularization if they have a non-healing ulcer.
Study: NCT06682741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: supervised exercise training; twice a week for 12 months
Study: NCT06682884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib 100 mg
Description: Eligible patients will be registered to receive oral lorlatinib 100mg qd for 6-8 weeks each during the neoadjuvant therapy phase
Study: NCT06683313

Intervention type: COMBINATION_PRODUCT
Intervention: combination femoral nerve and popliteal sciatica block
Description: Combination of femoral nerve and popliteal sciatica block performed after knee surgery

Intervention type: COMBINATION_PRODUCT
Intervention: combination adductor canal and IPACK block
Description: Combination of adductor canal and IPACK block performed after knee surgery
Study: NCT06683521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Low-Dose Oral Food Challenge (OFC)
Description: All participants will undergo a supervised Low Dose OFC (300 mg food protein or amended) on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Low-Dose Oral Food Challenge (OFC)
Description: All participants will undergo a supervised Low Dose OFC (300 mg food protein or amended) on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Low-Dose Oral Food Challenge (OFC)
Description: All participants will undergo a supervised Low Dose OFC (300 mg food protein or amended) on Day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: At-Home Low-Dose Oral Food Challenge (OFC)
Description: Participants who tolerate the Day 1 Low Dose OFC will undergo a daily Low-Dose OFC (300 mg food protein or amended) at home on Days 2-7.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: At-Home Low-Dose Oral Food Challenge (OFC)
Description: Participants who tolerate the Day 1 Low Dose OFC will undergo a daily Low-Dose OFC (300 mg food protein or amended) at home on Days 2-7.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: At-Home Low-Dose Oral Food Challenge (OFC)
Description: Participants who tolerate the Day 1 Low Dose OFC will undergo a daily Low-Dose OFC (300 mg food protein or amended) at home on Days 2-7.
Study: NCT05291585

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balloon catheter thrombectomy
Description: Intracranial thrombectomy was conducted by using a balloon catheter in conjunction with aspiration as control group.
Study: NCT05097599

Intervention type: DRUG
Group type: OTHER
Intervention: lorlatinib
Description: This arm of the Strata PATH trial will assess the clinical benefit of Lorbrena® (lorlatinib) in ALK and ROS1 gene fusion positive solid tumors, as detected by Strata testing, with the exception of NSCLC.

Intervention type: DRUG
Group type: OTHER
Intervention: encorafenib + binimetinib
Description: This arm of the Strata PATH trial will assess the clinical benefit of Braftovi® (encorafenib) + Mektovi® (binimetinib) in BRAF p.v600X mutated solid tumors, as detected by Strata testing, with the exception of melanoma and colorectal cancer.

Intervention type: DRUG
Group type: OTHER
Intervention: talazoparib
Description: This arm of the Strata PATH trial will assess the clinical benefit of Talzenna® (talazoparib) in patients with advanced solid tumors harboring deep deletions or deleterious mutations with LOH in BRCA1/2 and PALB2, as detected by Strata testing, excluding HER2 negative breast cancer.

Intervention type: DRUG
Group type: OTHER
Intervention: sacituzumab govitecan
Description: This arm of the Strata PATH trial will assess the clinical benefit of Trodelvy® (sacituzumab govitecan) in patients with advanced solid tumors and are Trop2 Treatment Response Score High (Trop2 TRS-H), as detected by Strata testing, excluding triple negative breast cancer, hormone receptor positive/ human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer, metastatic urothelial cancer, non-small cell lung (NSCLC) cancer, small cell lung cancer (SCLC), head and neck cancer, colorectal cancer (CRC), and endometrial cancer.

Intervention type: DRUG
Group type: OTHER
Intervention: axitinib
Description: This arm of the Strata PATH trial will assess the clinical benefit of Inlyta® (axitinib) in patients with advanced solid tumors and are Angiogensis Inhibitor Treatment Response Score High (Angio TRS-H), as detected by Strata testing, excluding renal cell carcinoma, alveolar soft part sarcoma, and solitary fibrous tumors.

Intervention type: DRUG
Group type: OTHER
Intervention: Fam-Trastuzumab Deruxtecan-Nxki
Description: This arm of the Strata PATH trial will assess the clinical benefit of Enhertu ® in patients with advanced solid tumors with Her2 overexpression

Intervention type: DRUG
Group type: OTHER
Intervention: enfortumab vedotin
Description: This arm of the Strata PATH trial will assess the clinical benefit of Padcev® in patients with advanced solid tumors with nectin-4 overexpression
Study: NCT04709172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil 400mg
Description: Cefditoren pivoxil 400mg bid for 7 days
Study: NCT05064826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Emergency Department Observation Units (EDOU) would allow the highest risk patients - those presenting for nonfatal overdose - to receive their first dose of BUP before leaving the ED.~Operationally defined to include placement in an observation unit and/or placement under observation status with care provided by Emergency Medicine and/or other services (e.g., Internal medicine, Psychiatry)
Study: NCT04980664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated intervention strategies
Description: Implementation of integrated intervention strategies to reduce the proportion of indicated-but-not-treated CHB patients.
Study: NCT05878990

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally-tailored Tobacco Treatment
Description: Weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally-tailored Tobacco Treatment
Description: Weekly telephone calls with a certified tobacco treatment specialist (CTTS) for 6 weeks. The culturally-tailored tobacco intervention content by week via telephone call with the CTTS includes among others: Reasons and Motivations for Quitting, Benefits of Quitting, Stress Management and Discussion about Environmental Influences.
Study: NCT04642456

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EOS stereoradiographic full body exam
Description: Every subject included in the study will undergo a stereoradiographic full body EOS exam completed with Gravity Line (GL) location, recorded by a force plate on the floor

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EOS stereoradiographic full body exam
Description: Every subject included in the study will undergo a stereoradiographic full body EOS exam completed with Gravity Line (GL) location, recorded by a force plate on the floor

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Balance Assessment Scale 2
Description: Repeating the newly developed balance test (test-retest reliability) within 2 weeks after first measurement

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Trunk strength measurement with EMG 2
Description: Repeating the trunk strength protocol with EMG within 2 weeks after the first measurement (test-retest reliability)
Study: NCT04954131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Candidate Vaccine, SCB-2019
Description: 30 μg of SCB-2019 antigen, and 1.5 mg CpG 1018 and 0.75 mg Alhydrogel as adjuvants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution (0.9%)
Study: NCT06383559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib and Sintilimab
Description: XELOX regimen combined with Sintilimab and Lenvatinib
Study: NCT06375590

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation
Description: Transcatheter treatment of bicuspid stenosis with the Navitor platform
Study: NCT05474625

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Laser Therapy
Description: For each 25 cm² of painful area, 1.02 minutes of treatment will give in the analgesic phase, with an energy of 8.0 watt, a dose of 5 Joules/ cm², a frequency of 25 Hertz(Hz) and a total energy of 125 joules. The application time for one session was approximately 15 minutes. Total 15 sessions will be applied to the neck area for a period of 3 weeks, 5 days a week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: This treatment was applied to the cervical paravertebral region with a direct contact with the skin with the aid of an ultrasonic gel, at a dose of 1 megahertz(MHz) and 1.5 Watt/cm² for 4 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous nerve stimulation (TENS)
Description: TENS was performed using 4 adhesive electrodes 5 × 5 cm size in the cervical paravertebral region, 80 Hertz (Hz) frequency and 180 miliseconds current for 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: A specific program consisted of 15 minutes exercise sessions was provided under the supervision of a physiotherapist . All patients will perform isometric strengthening exercises, active range of motion exercises, and cervical region stretching exercises for 15 sessions (during 3 weeks, on weekdays).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: A specific program consisted of 15 minutes exercise sessions was provided under the supervision of a physiotherapist . All patients will perform isometric strengthening exercises, active range of motion exercises, and cervical region stretching exercises for 15 sessions (during 3 weeks, on weekdays).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: A specific program consisted of 15 minutes exercise sessions was provided under the supervision of a physiotherapist . All patients will perform isometric strengthening exercises, active range of motion exercises, and cervical region stretching exercises for 15 sessions (during 3 weeks, on weekdays).
Study: NCT05647421

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation
Description: after phacoemulsification of the cataract , implantation of Acrysof IQVIVITY IOL .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation
Description: after phacoemulsification of the cataract , implantation of Acrysof IQVIVITY IOL .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation
Description: after phacoemulsification of the cataract , implantation of TECNIS Synergy™ Intraocular Lens (Model ZFR00V )

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation
Description: after phacoemulsification of the cataract , implantation of TECNIS Synergy™ Intraocular Lens (Model ZFR00V )
Study: NCT05107440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BREATHE
Description: A virtual, multidisciplinary, patient-centred self-management program for long COVID. The BREATHE program provides education on Breathing, Rest/recovery, Education, Activity management, Thinking/cognition, Healthy voice strategies, and Eating/nutrition.
Study: NCT04753736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine administration of hCG-activated peripheral blood mononuclear cells
Description: Intrauterine administration of hCG-activated peripheral blood mononuclear cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrauterine administration of hCG-activated peripheral blood mononuclear cells
Description: Intrauterine administration of hCG-activated peripheral blood mononuclear cells
Study: NCT05940402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral tablets
Study: NCT06118723

Intervention type: PROCEDURE
Intervention: Supramaximal resection
Description: Supramaximal resection. Tumor resection continues until either the FLAIR abnormalities have been resected based on the neuronavigation (after updating the navigation intraoperatively), or when subcortical tracts are identified with intraoperative stimulation.

Intervention type: PROCEDURE
Intervention: Maximal safe resection
Description: Maximal safe resection. Tumor resection continues until maximal safe resection has been achieved as by the neurosurgeon's opinion.
Study: NCT06225856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY201
Description: Oral administration under fasting state.
Study: NCT05210829

Intervention type: DIAGNOSTIC_TEST
Intervention: stationary and trait anxiety scale
Description: survey

Intervention type: DIAGNOSTIC_TEST
Intervention: stationary and trait anxiety scale
Description: survey
Study: NCT04441281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traction of the cervix for IUD insertion
Description: Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traction of the cervix for IUD insertion
Description: Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD).
Study: NCT05982665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Molecular hydrogen
Description: Hydrogen gas, purity \>99.9%, flow rate 300 ml/min.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ambient air, flow rate 300 ml/min.
Study: NCT05742243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept (CTLA4-Ig) and nasal insulin (Humulin R®)
Description: Abatacept injected subcutaneously once per week and nasal insulin inhaled for 10 consecutive days initially and twice per week thereafter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept (CTLA4-Ig) and nasal placebo (0.9% sodium chloride)
Description: Abatacept injected subcutaneously once per week and nasal placebo inhaled for 10 consecutive days initially and twice per week thereafter
Study: NCT04782934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The YANG SENSOR is an active implantable device, for Real Time Continuous Glucose, Lactate and Ketone Measurement
Description: The YANG SENSOR is an active implantable device, that is intended to be implanted in the subcutaneous abdominal tissue, approximately 10mm below the skin. The SENSOR is battery powered. The battery is wirelessly recharged through the skin by the YANGEXD, using a charging coil ('Donut') applied to the skin with an adhesive patch at the level of the SENSOR. The 'Donut' also receives data from the sensor.
Study: NCT05929443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: END-IT intervention for nursing homes
Description: Complex intervention, as described in the arm/group descriptions
Study: NCT05878990

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Culturally-tailored Content Newsletters
Description: Weekly newsletters covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Preference Scale
Description: Survey to elicit preference on the decision-making interaction with healthcare provider. The survey uses a 5 point scale from 1 to 5 with 1 or 2 points representing Active Control Preference; 3 or 4 representing a Collaborative Control Preference and 5 representing a Passive Control Preference.
Study: NCT05417048

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: Up to 5mL of blood via venipuncture

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: Up to 5mL of blood via venipuncture

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: Up to 5mL of blood via venipuncture
Study: NCT04535609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavodelpar
Description: Once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily
Study: NCT06126809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steep-tRAS
Description: Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flat-tRAS
Description: Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-tRAS
Description: Stimulation will be delivered via the NeuroConn Direct Current Stimulator Plus Multiple Channels, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research.
Study: NCT06683521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised High-Dose Oral Food Challenge (OFC)
Description: Participants who tolerate the Days 1-7 Low Dose OFC will undergo a supervised High Dose OFC (maximum 3000 mg food protein) on Day 8.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised High-Dose Oral Food Challenge (OFC)
Description: Participants who tolerate the Days 1-7 Low Dose OFC will undergo a supervised High Dose OFC (maximum 3000 mg food protein) on Day 8.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised High-Dose Oral Food Challenge (OFC)
Description: Participants who tolerate the Days 1-7 Low Dose OFC will undergo a supervised High Dose OFC (maximum 3000 mg food protein) on Day 8.
Study: NCT05950425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aspiration training
Description: Pre-test application; All mothers whose children are hospitalized in the PICU will be filled in the questionnaires after verbally expressing and signing the informed consent before being admitted to the intensive care unit and starting the education.~In practice; The mother of the child who is planned to be discharged from the intensive care unit is given training a week before. Aspiration training will be given to the Experimental I group with the video method, and to the Experimental II group with the picture training booklet method. The materials of these trainings will be given to the mothers and they will be asked to look after them when they come to the next care.~Final test application; scales will be filled in the mother on the day of the child's discharge.
Study: NCT05878990

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Content Newsletter or Passive Content Newsletter
Description: Based on the answers to the Control Preference Scale, participants will receive the appropriate weekly newsletter (active content or passive content). Newsletters are covering topics such as Race and Smoking, Nicotine Replacement Therapy (NRT) Reasons and Motivations for Quitting, Benefits of Quitting and other related topics presented in a more passive or active manner.